Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trainline shares 'unfairly discounted', says Shore Capital

(Sharecast News) - Shore Capital has reiterated a 'buy' rating for ticketing platform Trainline, saying the stock is being "unfairly discounted" by the market at current levels. Trainline shares jumped on Thursday after the company provided a first-half update that showed trading was tracking ahead of full-year expectations.

While full-year guidance was unchanged - net ticket sales are expected to grow 6-9% and revenues by 0-3% - Trainline said that adjusted EBITDA growth should come in at the top end of the 6-9% guidance range due to operating leverage and work on costs.

The result, Shore Capital said, is a 2% upgraded to its adjusted EBITDA forecast from £170.8m to £173m.

Looking ahead, the broker said: "We believe TRN's equity is being unfairly discounted due to wider UK government noise. This leaves the Group trading on a 7x EV/EBITDA multiple (14x PER), despite improving margins and a low double-digit FCFY.

"TRN is well positioned, in our view, to take advantage of the growing digitalisation of the UK rail network, explore European TAM opportunities in line with planned increased carrier competition, whilst also leveraging the proprietary technology platform for further customer engagement and B2B potential."

Trainline shares were up 7.4% at 279.2p by 1202 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.